Summary
Low-molecular-weight (LMW) heparin has been compared to standard unfractionated (UF) heparin in a total of 49 patients on hemodialysis and hemofiltration in order to determine the necessary therapeutic dose and its effect on the coagulation system. A LMW heparin dose corresponding to 50% of the normal UF heparin dose was found to produce similar plasma heparin levels (anti-FXa-U/ml) in particular on minimal heparinization. At higher doses, UF heparin produced a more marked increase in plasma-heparin than did LMW heparin. Highly significant differences were found between UF and LMW heparin in their effects on PTT and thrombin time. Partial thromboplastin time (PTT) increased under UF heparin by an average of 120 s whereas LMW heparin only produced an increase of 5–7 s. Thrombin time was increased by 250–280 s under UF heparin and by 5–8 s under LMW heparin. With this LMW heparin dose of 50% of the UF heparin dose, no thrombosis of the extracorporal system occurred and no macroscopic detectable thrombotic material was found in the dialyzers or filters. No significant differences were observed between the effects of UF and LMW heparin on Factor VIII activity and fibrin monomers, so that a difference in coagulation activation between the two heparins can be excluded. Furthermore, there were no changes in thromboplastin time according to Quick, fibrinogen, antithrombin III, plasminogen, and a2-antiplasmin. Thus effective Anti-FXa levels and by similar antithrombotic activity, LMW heparin will probably present less of a bleeding risk because of its reduced effect on PTT and thrombin time. LMW heparin therefore appears to be a good alternative to UF heparin for patients with renal insufficiency requiring dialysis. LMW heparin is indicated in particular in patients at bleeding risk, with diabetic retinopathy, on therapy with oral anticoagulants or platelet aggregation inhibitors, and with thrombocytopenia.
Similar content being viewed by others
Abbreviations
- F:
-
Faktor
- FFA:
-
Free Fatty Acids=freie Fettsäuren
- LMW-Heparin:
-
Low Molecular Weight Heparin=niedermolekulares Heparin
- LPL:
-
Lipoprotein-Lipase
- PTT:
-
Partial Thromboplastin Time=Partielle Thromboplastinzeit
- UF-Heparin:
-
unfraktioniertes Heparin
Literatur
Augustin J, Greten H (1979) The Role of Lipoprotein Lipase-Molecular Properties and Clinical Relevance. In: Paoloetti R, Gotto AM Jr (Hrsg) Atherosclerosis Reviews, Vol 5. Raven Press, New York, pp 91–124
Barrowcliffe TW, Johnson EA, Eggleton AC, Kemball-Cook C, Thomas DP (1979) Anticoagulant Activities of High and Low Molecular Weight Heparin Fractions. Brit J Haematol 41:573–583
Bengtsson G, Olivesona R, Hook M, Riesenfeld J, Lindendahl U (1980) Interaction of lipoprotein lipase with native and modified heparin-like polysaccharides. Biochem J 189:625–633
Carter CJ, Kelton JG, Hirsh J, Santos AV, Gent M (1982) The Relationship between the Hemorrhagic and Antithrombotic Properties of Low Molecular Weight Heparin in Rabbits. Blood 59:1239–1245
Carter CJ, Kelton JG, Hirsh J, Gent M (1981) Relationship between the Antithrombotic and Anticoagulant Effects of Low Molecular Weight Heparin. Thrombosis 21:169–174
Harenberg J, Augustin J, Haberbosch W, Weber E, Zimmermann R (1984) Pharmakodynamisches Verhalten niedermolekularen Heparins. 3. Kongress für Thrombose und Blutstillung, Bern 1984, S 41
Holmer E (1980) Anticoagulant properties of Heparin und Heparin Fractions. Scand J Haematol [Suppl 25]:25–39
Holmer E, Mattson C, Nilsson S (1982) Anticoagulant and Antithrombotic effects of Heparin and Low Molecular Weight Heparin Fragment in Rabbits. Thrombosis Res 25:475–485
Holmer E, Lindahl U, Backström G, Thunberg L, Sandberg H, Söderström G, Andersson L-O (1980) Anticoagulant Activities and Effects on Platelets of a Heparin Fragment with high Affinity for Antithrombin. Thrombosis Res 18:861–869
Huisse MG, Guillin MC, Bezeaud A (1982) Heparin-associated thrombocytopenia. In vitro effects of different molecular weight heparin fractions. Thrombosis Res 27:485–490
Kakkar VV, Djazaeri B, Fok J, Fletcher M, Scully MF, Westwick J (1982) Low-molecular-weight heparin and prevention of postoperative deep-vein thrombosis. Brit Med J 284:375–379
Köstering H (1981) Die Thromboembolien. Schattauer, Stuttgart
Kramer P (1982) Arterio-venöse Hämofiltration. Vandenhoeck&Ruprecht, Göttingen Zürich
Lindner A, Charra D, Sherrard DF, Scribner BH (1974) Accelerated atherosclerosis in prolonged maintenance hemodialysis. New Engl J Med 290:697–701
Niessner H, Lechner K (1980) Ärztliche Überwachung der Heparin-Therapie. In: Marx R, Thies HA (Hrsg) Kontrolle von Antithrombotika. Editiones Roche, Basel, S 37–46
Nilsson-Ehle P (1982) Regulation of Lipoprotein Lipase. In: Carlson LA, Pernow P (eds) Metabolic Risk Factors in Ischemic Cardiovascular Disease. Raven Press, New York, pp 49–57
Remuzzi G, Benigni N, Dodesini P, Schieppati A, Gotti E, Livio M, Mecca G, Donati MB, De Geatano G (1982) Platelet function in patients on maintenance hemodialysis: depressed or enhanced? Clin Nephrol 17:60–63
Salzman EW, Rosenberg RD, Smith MH, Lindon JN, Favreau L (1980) Effect of Heparin and Heparin Fractions on Platelet Aggregation. J Clin Invest 65:64–73
Schrader J, Köstering H, Kramer P, Scheler F (1982) Anti-thrombin III-Substitution bei dialysepflichtiger Niereninsuffizienz. Dtsch med Wschr 107:1847–1850
Schrader J, Bohnsack W, Kaiser H, Eisenhauer T, Kramer P, Köstering H (1982) Antikoagulation bei kontinuierlicher arterio-venöser Hämofiltration. In: Kramer P (Hrsg) Arterio-venöse Hämofiltration. Vandenhoeck&Ruprecht, Göttingen Zürich, S 67–80
Sieberth H-G, Kindler J, Vlaho M, Glöckner WM, Freiberg J, Pelzer R (1982) Langzeitergebnisse der chronisch-intermittierenden Dialysebehandlung. Med Welt 33:1363–1366
Stibbe W, Walli A, Schrader J, Seidel D (1984) Biochem Biophys Acta (in Vorbereitung)
Swartz RD, Port FK (1979) Preventing hemorrhage in high-risk hemodialysis: Regional versus low-dose heparin. Kid Int 16:513–518
Swartz RD (1981) Hemorrhage during High-Risk Hemodialysis. Using controlled Heparinization. Nephron 28:65–69
Vinazzer H, Stemberger A, Haas S (1983) Influence of heparin and of low molecular weight heparin analogues on fibrinolysis. In: Davidson JF, Bachmann F, Bouvier CA, Kruithof EKO (Hrsg) Progress in Fibrinolysis, Vol VI. Churchill Livingstone, Edinburgh London Melbourne New York, pp 571–573
Vogel GE, Kopp KF (1978) The conflict between anticoagulation and hemostasis during hemodialysis. Int J Artif Organs 1:181–186
Yin ET, Wessler S, Stoll PJ (1971) Biological Properties of the Naturally Occuring Plasma Inhibitor to Activated Factor X. J Biol Chem 246:3703–3711
Zilversmit DB (1973) A proposal linking atherogenesis to the interaction of endothelial Lipoprotein Lipase with triglyceride-rich Lipoproteins. Circ Res 33:633–638
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Schrader, J., Rieger, J., Müschen, H. et al. Anwendung von niedermolekularem Heparin bei Hämodialysepatienten. Klin Wochenschr 63, 49–55 (1985). https://doi.org/10.1007/BF01733067
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01733067